46 related articles for article (PubMed ID: 17534699)
1. Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival.
Stein GY; Yosef N; Reichman H; Horev J; Laser-Azogui A; Berens A; Resau J; Ruppin E; Sharan R; Tsarfaty I
PLoS One; 2012; 7(9):e45969. PubMed ID: 23049908
[TBL] [Abstract][Full Text] [Related]
2. Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.
Zhang Z; Li M; Rayburn ER; Hill DL; Zhang R; Wang H
Am J Pharmacogenomics; 2005; 5(6):397-407. PubMed ID: 16336004
[TBL] [Abstract][Full Text] [Related]
3. Survivin, cancer networks and pathway-directed drug discovery.
Altieri DC
Nat Rev Cancer; 2008 Jan; 8(1):61-70. PubMed ID: 18075512
[TBL] [Abstract][Full Text] [Related]
4. Effect of hepatocyte growth factor (HGF) on the level of Survivin & XIAP expression in several human cancer cell lines, after treating with DNA damaging agent.
Keyhanian K; Edalat R; Oghalaei A; Askary N; Golshani A; Salehi M; Sarrami-Forooshani R; Shokrgozar MA
Mol Cell Biochem; 2007 Oct; 304(1-2):199-205. PubMed ID: 17534699
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
6. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Saitou Y; Sugimoto K; Nakano T
Oncol Rep; 2005 Nov; 14(5):1311-6. PubMed ID: 16211302
[TBL] [Abstract][Full Text] [Related]
7. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy.
Yang L; Cao Z; Yan H; Wood WC
Cancer Res; 2003 Oct; 63(20):6815-24. PubMed ID: 14583479
[TBL] [Abstract][Full Text] [Related]
8. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
[TBL] [Abstract][Full Text] [Related]
9. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling.
Takeuchi H; Kim J; Fujimoto A; Umetani N; Mori T; Bilchik A; Turner R; Tran A; Kuo C; Hoon DS
Clin Cancer Res; 2005 Nov; 11(21):7621-8. PubMed ID: 16278380
[TBL] [Abstract][Full Text] [Related]
10. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
11. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax.
Kawakami H; Tomita M; Matsuda T; Ohta T; Tanaka Y; Fujii M; Hatano M; Tokuhisa T; Mori N
Int J Cancer; 2005 Jul; 115(6):967-74. PubMed ID: 15729715
[TBL] [Abstract][Full Text] [Related]
13. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection.
Fan S; Gao M; Meng Q; Laterra JJ; Symons MH; Coniglio S; Pestell RG; Goldberg ID; Rosen EM
Oncogene; 2005 Mar; 24(10):1749-66. PubMed ID: 15688034
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies.
Jiang WG; Martin TA; Parr C; Davies G; Matsumoto K; Nakamura T
Crit Rev Oncol Hematol; 2005 Jan; 53(1):35-69. PubMed ID: 15607934
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
